These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37992608)

  • 1. Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy.
    Kifjak D; Hochmair M; Sobotka D; Haug AR; Ambros R; Prayer F; Heidinger BH; Roehrich S; Milos RI; Wadsak W; Fuereder T; Krenbek D; Fazekas A; Meilinger M; Mayerhoefer ME; Langs G; Herold C; Prosch H; Beer L
    Eur J Radiol; 2024 Jan; 170():111198. PubMed ID: 37992608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the
    Goksel S; Cengiz A; Ozturk H; Yurekli Y
    J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
    Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
    Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F
    Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
    Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
    Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of
    Ling T; Zhang L; Peng R; Yue C; Huang L
    Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic tumor volume derived from
    Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
    Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
    J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab.
    Eude F; Guisier F; Salaün M; Thiberville L; Pressat-Laffouilhere T; Vera P; Decazes P
    Ann Nucl Med; 2022 Mar; 36(3):224-234. PubMed ID: 35060071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.